The prognostic value of aspartate beta-hydroxylase in early breast cancer.

Purpose Aspartate beta-hydroxylase (ASPH) is a transmembrane protein involved in cancer progression, which has been shown to imply a worse prognosis in several solid tumors. The aim of the present study was to further investigate the prognostic value of ASPH in early breast cancer. Methods ASPH expression was investigated through immunohistochemistry in a cohort of 153 breast cancer patients with long-term follow-up, and correlated with clinical–pathological features plus all-cause and breast-cancer-specific mortality. Appropriate statistics were utilized. Results ASPH negatively correlated with all-cause and breast-cancer-specific mortality. Conclusions The results of this cohort study support the prognostic value of ASPH in early breast cancer.